{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:20:33Z","timestamp":1722000033198},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.bjhh.2016.02.006","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T14:38:15Z","timestamp":1458398295000},"page":"99-105","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders"],"prefix":"10.1016","volume":"38","author":[{"given":"Ana Marcela Rojas","family":"Fonseca-Hial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Parisio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Salvador Rodrigues","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bjhh.2016.02.006_bib0165","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/bmt.2013.51","article-title":"Hematopoietic SCT in Europe: data and trends in 2011. European Group for Blood and Marrow Transplantation","volume":"48","author":"Passweg","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"10.1016\/j.bjhh.2016.02.006_bib0170","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","article-title":"Trends in utilization and survival after autologous hematopoietic cell transplantation in North America from 1995 to 2005: Significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age","volume":"19","author":"McCarthy","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"10.1016\/j.bjhh.2016.02.006_bib0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.exphem.2012.01.012","article-title":"Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen","volume":"40","author":"Reddy","year":"2012","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.bjhh.2016.02.006_bib0180","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2011.05.002","article-title":"Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach","volume":"17","author":"Reddy","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1016\/j.bjhh.2016.02.006_bib0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.exphem.2012.01.014","article-title":"Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies","volume":"40","author":"Chinratanalab","year":"2012","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.bjhh.2016.02.006_bib0190","first-page":"271","volume":"24","author":"Khouri","year":"2011","journal-title":"Allogeneic stem cell transplantation in follicular lymphoma"},{"issue":"12","key":"10.1016\/j.bjhh.2016.02.006_bib0195","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/bmt.2013.56","article-title":"Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?","volume":"48","author":"Chaudhary","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.bjhh.2016.02.006_bib0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbmt.2010.07.008","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence based review","volume":"17","author":"Oliansky","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.bjhh.2016.02.006_bib0205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbmt.2010.01.008","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review","volume":"16","author":"Oliansky","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"10.1016\/j.bjhh.2016.02.006_bib0210","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/bmt.2012.266","article-title":"The role of allogeneic hematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)","volume":"48","author":"Papageorgiou","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.bjhh.2016.02.006_bib0215","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbmt.2011.09.009","article-title":"The evolving role of stem cell transplants in lymphomas","volume":"18","author":"Jantunen","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.bjhh.2016.02.006_bib0220","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/107327481101800405","article-title":"Hematopoietic cell transplantation for lymphomas","volume":"18","author":"Ayala","year":"2011","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.bjhh.2016.02.006_bib0225","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"10.1016\/j.bjhh.2016.02.006_bib0230","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bjhh.2016.02.006_bib0235","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.hoc.2008.07.007","article-title":"Stem cell transplantation for Non-Hodgkin's lymphoma","volume":"22","author":"Wrench","year":"2008","journal-title":"Hematol Oncol Clin N Am"},{"issue":"12","key":"10.1016\/j.bjhh.2016.02.006_bib0240","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.exphem.2010.08.012","article-title":"Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies","volume":"38","author":"Blaise","year":"2010","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.bjhh.2016.02.006_bib0245","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bjhh.2016.02.006_bib0250","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bjhh.2016.02.006_bib0255","first-page":"825","article-title":"1994 Consensus Conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.bjhh.2016.02.006_bib0260","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versushost syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"15","key":"10.1016\/j.bjhh.2016.02.006_bib0265","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bjhh.2016.02.006_bib0270","unstructured":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva: Estimativa 2014, incid\u00eancia de c\u00e2ncer no Brasil, Linfoma n\u00e3o Hodgkin [cited 2 September 2014]. Available from: http:\/\/www.inca.gov.br\/estimativa\/2014\/sintese-de-resultados-comentarios.asp."},{"key":"10.1016\/j.bjhh.2016.02.006_bib0275","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica. Pesquisa Nacional por Amostras de Domic\u00edlios. Available from: [cited 15 September 2014]. http:\/\/www.ibge.gov.br\/home\/estatistica\/populacao\/trabalhoerendimento\/pnad98\/saude\/analise.shtm."},{"issue":"6","key":"10.1016\/j.bjhh.2016.02.006_bib0280","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"10.1016\/j.bjhh.2016.02.006_bib0285","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ph7050530","article-title":"Barriers to the access and use of rituximab in patients with Non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a physician survey","volume":"7","author":"Baer Ii","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bjhh.2016.02.006_bib0290","series-title":"Parecer T\u00e9cnico: o uso do Rituximabe no tratamento do Linfoma n\u00e3o-Hodgkin, de c\u00e9lula B, baixo grau CD20","year":"2009"},{"key":"10.1016\/j.bjhh.2016.02.006_bib0295","unstructured":"Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012 [cited 19 May 2013]. Available from: http:\/\/www.cibmtr.org."},{"issue":"8","key":"10.1016\/j.bjhh.2016.02.006_bib0300","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.bjhh.2016.02.006_bib0305","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0b013e328365a151","article-title":"Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes","volume":"20","author":"Rezvani","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bjhh.2016.02.006_bib0310","doi-asserted-by":"crossref","first-page":"494","DOI":"10.14694\/EdBook_AM.2012.32.238","article-title":"What is the role of transplantation for indolent lymphoma?","author":"Cassaday","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.bjhh.2016.02.006_bib0315","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent Non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bjhh.2016.02.006_bib0320","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","article-title":"Allotransplantation for patients age \u226440 years with Non-Hodgkin lymphoma: encouraging progression-free survival","volume":"20","author":"McClune","year":"2014","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848416300068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848416300068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T12:00:57Z","timestamp":1600344057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1516848416300068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1516848416300068"],"URL":"https:\/\/doi.org\/10.1016\/j.bjhh.2016.02.006","relation":{},"ISSN":["1516-8484"],"issn-type":[{"value":"1516-8484","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Hematologia e Hemoterapia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjhh.2016.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}